Therapeutics News

Long-term use of a combination halobetasol propionate and tazarotene lotion cleared psoriasis in patients with skin of color as well as white patients, according to a poster presentation at the Skin of Color Update virtual meeting.

Biologic therapies did not put individuals undergoing surgery at greater risk for post-operative skin and soft tissue infections, according to a study.

Dupixent reduced both itch and hives in patients with moderate to severe chronic spontaneous urticaria in a pivotal phase 3 trial, Regeneron and Sanofi announced in a press release.

In this video, Joel M. Gelfand, MD, MSCE, professor of dermatology and epidemiology at the University of Pennsylvania Perelman School of Medicine, discussed phase 2b data on roflumilast foam presented at AAD VMX 2021.

In this video, Joel M. Gelfand, MD, MSCE, professor of dermatology and epidemiology at the University of Pennsylvania Perelman School of Medicine, spoke with Healio about research on deucravacitinib presented at AAD VMX 2021.

Journey Medical will acquire Qbrexza from Dermira, according to a press release.

Patients being treated with tumor necrosis factor inhibitors or methotrexate who acquired COVID-19 did not experience elevated hospitalization or mortality rates, according to a study.

Azura Ophthalmics has raised $20 million in financing for registration studies of its lead clinical candidate for treatment of meibomian gland dysfunction, according to a press release.

Use of tumescent anesthesia allows for equal anesthetic distribution across large areas while decreasing the likelihood of lidocaine toxicity, according to a presentation at the American Society for Dermatologic Surgery annual meeting.

Dexmedetomidine may be an acceptable sedative to administer during dermatologic and cosmetic surgical procedures, according to findings presented at the American Society for Dermatologic Surgery annual meeting.